๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Application of PET/MRI in the Evaluation of the Efficacy of Neoadjuvant Therapy for Locally Advanced Rectal Cancer
NCT06653452Locally Advanced Rectal Cancer (LARC)
Peking Union Medical College Hospital
Not applicable
30
Beijing
2024-07-01
Recruiting
A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
NCT06447597Generalized Myasthenia Gravis
DrugB007
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
104
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Kunming
2024-07-01
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
Beijing, Guangzhou, Shanghai
2024-07-01
Not yet open
Accuracy Assessment of a Novel Gas Detection Approach in Dyslipidemia Diagnosis
NCT06486857Dyslipidemias, Gas Detection Method
Beijing Anzhen Hospital
Observational
1,000
Beijing
2024-07-01
Not yet open
TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
NCT06500091Soft Tissue Sarcoma, Melanoma
DrugsTQB2916·Doxorubicin Hydrochloride·Penpulimab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
54
Beijing, Zhengzhou, Changsha, Changchun, Jinan, Shanghai, Taiyuan, Tianjin
2024-07
Recruiting
Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
NCT06818916Delayed Platelet Engraftment, Neuroblastoma, Autologous Hematopoietic Stem Cell Transplantation
DrugHetrombopag
Beijing Children's Hospital
Not applicable
30
Beijing
2024-06-30
Not yet open
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
NCT06446388Advanced Solid Tumor
DrugsQLS31905·Iparomlimab and Tuvonralimab·Oxaliplatin·Capecitabine
Qilu Pharmaceutical Co., Ltd.
Phase 2
360
Beijing
2024-06-30
Not yet open
Neoadjuvant Radiotherapy for High-risk UTUC
NCT06472752Urothelial Carcinoma of the Renal Pelvis and Ureter
Peking University First Hospital
Observational
40
Beijing
2024-06-30
Active, closed
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
NCT06238843Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
DrugsIBI343·Irinotecan·Paclitaxel
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
464
Bengbu, Hefei, Lu'an, Wuhu, Beijing, Fuzhou, Lanzhou, Dongguan
2024-06-30
Recruiting
Guo's Aortic Arch Reconstruction: A Multicenter, Prospective Study of the Novel WeFlow-Tribranch System (GENIUS Study)
NCT06385379Aortic Arch Aneurysm
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
90
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Harbin, Jinan, Kunming
2024-06-30
Recruiting
Immuno-effect of Tฮฑ1 for Stage I NSCLC
NCT06598839Non Small Cell Lung Cancer
DrugThymalfasin
Yousheng Mao
Not applicable
40
Beijing
2024-06-30
Recruiting
Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath
NCT06518655Pulmonary Nodules, Multiple, Pulmonary Nodules, Solitary, Lung Cancer
ChromX Health
Observational
3,000
Beijing, Foshan, Guangzhou, Wuhan, Shanghai, Chengdu
2024-06-30
Active, closed
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
NCT06462222Leptomeningeal Metastasis
Guangzhou Medical University
Phase 1/2
45
Huizhou, Beijing, Shanghai
2024-06-30
Recruiting
Pilot Study on Evaluating the Geroprotective Effect of Metformin
NCT06459310Metformin, Aging
DrugMetformin Hydrochloride
Xuanwu Hospital, Beijing
Phase 2
130
Beijing
2024-06-30
Recruiting
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)
NCT05224960Decompensated Cirrhosis
DrugUC-MSCs
Beijing 302 Hospital
Phase 2
140
Lanzhou, Guangzhou, Sanya, Wuhan, Shanghai, Kashgar, Beijing
2024-06-27
Recruiting
Efficacy and Safety of the Liquid Embolic System (Tonbridge) for Endovascular Treatment of Cerebrovascular Malformations
NCT06479343Intracranial Arteriovenous Malformations
Ton-Bridge Medical Tech. Co., Ltd
Not applicable
170
Guangzhou, Zhengzhou, Nanjing, Changchun, Shenyang, Jinan, Beijing, Chengdu
2024-06-27
Recruiting
Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer
NCT06306755Esophageal Cancer, Gastric Cancer, Precision Screening, Sequential Screening
Peking University Cancer Hospital & Institute
Not applicable
21,000
Beijing
2024-06-25
Active, closed
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
10,000
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Cangzhou, Shijiazhuang, Harbin
2024-06-25
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587Generalized Myasthenia Gravis
DrugCladribine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Anhui Sheng, Beijing, Guangzhou, Zunyi, Shijiazhuang, Zhengzhou, Changsha, Wuhan
2024-06-25
Recruiting
Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation
NCT06536400Solid Tumors
DrugHSK42360
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
316
Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Changsha, Nanjing, Shanghai
2024-06-25
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guiyang, Shijiazhuang
2024-06-25
Active, closed
LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.
NCT06351020Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
DrugsLM-302·Apatinib·Irinotecan
LaNova Medicines Zhejiang Co., Ltd.
Phase 3
387
Beijing, Shanghai
2024-06-24
Recruiting
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06307795Locally Advanced or Metastatic Solid Tumors
DrugANS014004
Avistone Biotechnology Co., Ltd.
Phase 1
63
Beijing, Harbin, Zhengzhou, Jinan, Shanghai
2024-06-24
Recruiting
SIM0718 Treatment of Asthma Clinical Study
NCT06488755Asthma; Eosinophilic
Simcere Pharmaceutical Co., Ltd
Phase 3
418
Beijing
2024-06-23
Recruiting
Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV
NCT06782685Advanced Pancreatic Cancer (Part 1)
DrugsIrinotecan Liposomal·Ivonescimab·Oxaliplatin·Bevacizumab
Dai, Guanghai
Phase 1/2
138
Beijing
2024-06-23
Active, closed
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT06378177Head and Neck Squamous Cell Carcinoma
DrugsToripalimab·Paclitaxel
Lyvgen Biopharma Holdings Limited
Phase 2
64
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha
2024-06-21
Recruiting
Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
NCT06468215Carcinoma, Endometrioid, Fertility Preservation
Peking University People's Hospital
Not applicable
16
Beijing
2024-06-21
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Beijing, Chongqing, Dongguan, Guangzhou, Hangzhou, Hengyang, Jining, Nanjing
2024-06-20
Recruiting
TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination
NCT06478537Immune Thrombocytopenia
DrugsHetrombopag Olamine·Hetrombopag·Aspirin
Peking Union Medical College Hospital
Phase 2
56
Beijing
2024-06-20
Not yet open
A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.
NCT06369935Relapsed/Refractory Multiple Myeloma
DrugEquecabtagene Autoleucel
Peking University People's Hospital
Observational
260
Beijing
2024-06-20
Recruiting
Transcutaneous Auricular Vagus Nerve Stimulation Prevents Postoperative Delirium in Elderly Patients
NCT06421077Vagus Nerve Stimulation
Beijing Tiantan Hospital
Not applicable
1,776
Beijing
2024-06-20
Recruiting
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
NCT06454968Marginal Zone Lymphoma
Peking Union Medical College Hospital
Phase 2
45
Beijing
2024-06-20
Recruiting
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
DrugsLevoleucovorin·Fluorouracil·Leucovorin·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 1/2
220
Beijing, Fuzhou, Wuhan, Changsha, Shanghai, Chengdu
2024-06-20
Active, closed
A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
NCT06433531Generalized Pustular Psoriasis
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
9
Beijing, Guangzhou, Shijiazhuang, Shenyang, Chengdu, Hangzhou
2024-06-19
Recruiting
A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06341335Gastric and Gastroesophageal Junction Adenocarcinoma
Akeso
Phase 3
506
Beijing
2024-06-19
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone
Celgene
Phase 3
850
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou
2024-06-19
Recruiting
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
NCT06316856T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2
54
Beijing, Shanghai, Chengdu
2024-06-18
Recruiting
A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
NCT06471257Asthma
AstraZeneca
Phase 3
1,000
Baotou, Beijing, Changchun, Changsha, Chengdu, Chizhou, Chongqing, Dazhou
2024-06-17
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288Heart Failure
DrugsVicadrostat·Empagliflozin
Boehringer Ingelheim
Phase 3
6,000
Baotou, Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Dalian
2024-06-17
Recruiting
A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
NCT06378593Solid Tumors With FGFR2 Alterations, Adult
Drug3HP-2827
3H (Suzhou) Pharmaceuticals Co., Ltd.
Phase 1/2
130
Beijing, Shanghai
2024-06-17
Recruiting
the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children
NCT05911893Malnutrition, Child, Malnourishment, Nutritional Deficiency, Undernutrition
Children's Hospital of Chongqing Medical University
Not applicable
200
Hefei, Beijing, Jilin City, Chongqing, Guangzhou, Guiyang, Changsha, Nanjing
2024-06-17
Active, closed
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
NCT05562947Neovascular Age-related Macular Degeneration, nAMD
DrugRanibizumab
Hoffmann-La Roche
Phase 3
68
Beijing, Chengdu, Guangzhou, Harbin, Qingdao, Shanghai, Shenyang, Taiyuan
2024-06-17
Recruiting
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
NCT06418477Monoclonal Gammopathy of Renal Significance
Peking University People's Hospital
Phase 2
20
Beijing, Guangzhou
2024-06-15
Recruiting
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
NCT06508983Relapsed/Refractory Multiple Myeloma
DrugsSG301·Pomalidomide·Dexamethasone
Hangzhou Sumgen Biotech Co., Ltd.
Phase 3
360
Beijing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Suzhou, Taiyuan, Xiโ€™an
2024-06-14
Recruiting
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
NCT06574568Relapsed or Refractory Multiple Myeloma
DrugYKST02
Excyte Biopharma Ltd
Phase 1
70
Beijing, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Dalian, Jinan
2024-06-14
Recruiting
Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease
NCT05831085Coronary Artery Stenosis
Duk-Woo Park, MD
Not applicable
1,500
Beijing, Hanzhou
2024-06-14
Recruiting
China Healthy Aging Cohort Study
NCT06472674Age Problem, Disability, Dementia, Death
Xuanwu Hospital, Beijing
Observational
6,780
Beijing
2024-06-13
Recruiting
Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)
NCT06813365Nonsmall-cell Lung Cancer
Dizal Pharmaceuticals
Phase 1
300
Beijing
2024-06-12
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754Non-small Cell Lung Cancer (NSCLC)
DrugsSteroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan·Dexamethasone
Merck Sharp & Dohme LLC
Phase 3
550
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2024-06-11
Active, closed
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621Triple Negative Breast Cancer(TNBC)
DrugsPumitamig·Nab-paclitaxel
Biotheus Inc.
Phase 3
392
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Foshan, Guangzhou
2024-06-11
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
DrugsSacituzumab tirumotecan·Nab-paclitaxel·Paclitaxel·Carboplatin
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Active, closed
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06448312Non-Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Pembrolizumab
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
406
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Dongguan
2024-06-07
Recruiting
Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort
NCT06399185Urinary Catheter, Catheter-related Bladder Discomfort, Dexmedetomidine, Esketamine
Peking University First Hospital
Phase 4
1,740
Beijing, Shenzhen
2024-06-06
Recruiting
Mobile Applet for Weight Management in Obese Heart Failure Patients
NCT06455878Heart Failure, Overweight and Obesity, Weight Loss, Heart Failure With Reduced Ejection Fraction
Heart Health Research Center
Not applicable
830
Beijing, Guangzhou, Langfang, Jixi, Luoyang, Shangqiu, Xinyang, Zhengzhou
2024-06-06
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 3
563
Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Guilin, Nanning, Cangzhou
2024-06-05
Recruiting
A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Pre-COPD Outcomes in Chinese Population
NCT06724848COPD
AstraZeneca
Observational
850
Beijing, Changsha, Chengdu, Guangzhou, Hefei, Nanjing, Nanning, Shanghai
2024-06-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2024-06-05
Recruiting
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
NCT06450067B-cell Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.
Observational
200
Beijing, Guangzhou, Zhengzhou, Wuhan, Xuzhou, Jinan, Shanghai, Chengdu
2024-06-05
Recruiting
A Trail of Sperstentยฎ Used for Residual Lesions of Femoropopliteal Arteries
NCT06539689Peripheral Arterial Disease, Stenosis, Dissection
FrontAce Scientific Co., Ltd
Not applicable
240
Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nantong, Shanghai
2024-06-04
Recruiting
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation
NCT06275555Extracorporeal Membrane Oxygenation Complication
Xiaotong Hou
Not applicable
154
Beijing
2024-06-03
Recruiting
Fractional Flow Reserve-guided Stenting Versus Medical Therapy in Atherosclerosis Renal Artery Stenosis
NCT06447740Renal Artery Stenosis Atherosclerotic, Secondary Hypertension Renal Arterial
Peking University First Hospital
Not applicable
200
Beijing
2024-06-03
Recruiting
Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
NCT06393361Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
DrugsDecitabine·Chidamide
Chinese PLA General Hospital
Phase 2
100
Beijing
2024-06-01
Not yet open
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study
NCT06435702Prostate Cancer
Peking University Third Hospital
Observational
108
Beijing
2024-06-01
Recruiting
Diagnostic Value of Deep Learning-Based Rapid MRI in Preoperative Evaluation of Acute Cholecystitis
NCT07551375Acute Cholecystitis
Peking Union Medical College Hospital
Observational
300
Beijing
2024-06-01
Recruiting
General Anesthesia vs Local Anesthesia for Endovascular Treatment in Patients With Unruptured Intracranial Aneurysm Using Flow Diverter
NCT06416657Intracranial Aneurysm
Ming Lv
Not applicable
188
Beijing
2024-06-01
Recruiting
Resting Energy Expenditure and Substrate Consumption in Cardiac Arrest Patients Under Target Temperature Management
NCT06575101Targeted Temperature Management, Cardiac Arrest, Resting Energy Expenditure, Nutrition
Tang Ziren
Observational
40
Beijing
2024-06-01
Active, closed
Establishment of Emergency Surgery Triage and Checklist Management System
NCT06501157Emergency Surgery, Triage, Checklist, Perioperative/Postoperative Complications
Peking Union Medical College Hospital
Observational
60
Beijing
2024-06-01
Active, closed
Subiculum Electrical Stimulation for Temporal Lobe Epilepsy With Biliteral Hippocampus Sclerosis(SESTB)
NCT06436547Epilepsy, Drug Resistant
Xuanwu Hospital, Beijing
Not applicable
6
Beijing
2024-06-01
Recruiting
Factors Influencing Physiological Hyperopia in Children
NCT06498947Myopia Progression
Beijing Tongren Hospital
Observational
1,006
Beijing
2024-06-01
Not yet open
Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer
NCT06443671Rectal Cancer
DrugCapeox
Peking University Cancer Hospital & Institute
Phase 2/3
132
Beijing
2024-06-01
Recruiting
Ultrasound-guided Stellate Ganglion Block for Treatment of Chronic Migraine in Adult
NCT06322407Chronic Migraine
Beijing Tiantan Hospital
Not applicable
206
Beijing
2024-06-01
Recruiting
HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC
NCT06548529HER2 Positive or Suspicious Positive Tumors
Peking University Cancer Hospital & Institute
Not applicable
30
Beijing
2024-06-01
Active, closed
Integrated Traditional Chinese and Western Medicine for Patellar Dislocation Pain: A Concurrent Non-Randomized Controlled Trial
NCT07613346Postoperative Pain After Patellar Dislocation Surgery
Peking University Third Hospital
Not applicable
80
Beijing
2024-06-01
Recruiting
Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma
NCT06961617Hepatocellular Carcinoma
Lion TCR Pte. Ltd.
Phase 1
10
Beijing
2024-06-01
Active, closed
Risk Stratification for Abdominal Emergency Surgery: a Cohort Study
NCT06501170Emergency Surgery
Peking Union Medical College Hospital
Observational
1,000
Beijing
2024-06-01
Recruiting
Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease
NCT06425120Coronary Heart Disease
DrugXuesaitong soft
China National Center for Cardiovascular Diseases
Phase 4
240
Beijing, Nantong
2024-06-01
Not yet open
Patient Education in the Clinical Management of Pessary
NCT06432218Pelvic Organ Prolapse
Peking Union Medical College Hospital
Not applicable
280
Beijing
2024-06
Recruiting
Exploring the Diagnostic Biomarkers of Cognitive Disorders in China
NCT06419101Biomarkers, Dementia
Cuibai Wei๏ผŒClinical Professor
Observational
3,000
Beijing
2024-05-30
Active, closed
A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors
NCT07131189Locally Advanced/Metastatic Solid Tumors
DrugFL115
Suzhou Forlong Biotechnology Co., Ltd
Phase 1
30
Beijing, Guangzhou, Jinan
2024-05-30
Recruiting
Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases
NCT06520774Aortic Arch Aneurysm, Penetrating Aortic Ulcer
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
103
Beijing, Changsha, Chengdu, Fuzhou, Hanzhou, Kunming, Nanjing, Shanghai
2024-05-30
Recruiting
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
NCT06363994Mantle Cell Lymphoma
DrugsBendamustine·Orelabrutinib·Rituximab
InnoCare Pharma Inc.
Phase 3
476
Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2024-05-29
Recruiting
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
NCT06428188Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus Acute, Sjogren's Syndrome
Essen Biotech
Phase 1/2
60
Beijing
2024-05-29
Recruiting
Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival
NCT06256354Cancer Surgery, Intraoperative Hypothermia, Targeted Temperature Management, Postoperative Delirium
Peking University First Hospital
Not applicable
3,992
Chizhou, Hefei, Maโ€™anshan, Beijing, Chongqing, Shenzhen, Shijiazhuang, Harbin
2024-05-29
Recruiting
AI-Enhanced Optimization of Acute Levodopa Challenge Test
NCT06949865Vascular Parkinsonism, Drug-induced Parkinsonism, Corticobasal Degeneration (CBD), Parkinson Disease (PD)
Beijing Tiantan Hospital
Observational
2,000
Beijing
2024-05-28
By invitation
A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma
NCT06424626Melanoma, Mucosal Melanoma, Metastatic Melanoma
DrugsAxitinib·Cadonilimab·Ivonescimab
Peking University Cancer Hospital & Institute
Phase 1
60
Beijing
2024-05-28
Recruiting
PET Imaging of 68Ga-Her2-affibody in Tumors with High Her2 Expression
NCT06289517Neoplasms
Peking University First Hospital
Not applicable
30
Beijing
2024-05-28
Active, closed
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT06470438Lymphoma, Non-Hodgkin, Refractory B-Cell NHL, Relapsed B-cell NHL
Janssen Research & Development, LLC
Phase 1
58
Beijing, Guangzhou, Hangzhou, Shanghai, Tianjin
2024-05-28
Recruiting
Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial
NCT06329635Aneurysmal Subarachnoid Hemorrhage, Vasospasm
DrugNicardipine
The Affiliated Hospital Of Guizhou Medical University
Not applicable
396
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanning, Guiyang, Kaili
2024-05-27
Recruiting
CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
NCT06389305B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia
Beijing GoBroad Hospital
Not applicable
213
Beijing
2024-05-27
Recruiting
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
NCT06417554Advanced Solid Tumors
DrugsSHR-A2102·Disitamab Vedotin·Adebrelimab
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
80
Beijing
2024-05-27
Recruiting
A Study of GLB-001 in Patients With Myeloid Malignancies
NCT06378437Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes
DrugGLB-001
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
108
Hefei, Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-05-24
Recruiting
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
NCT06375044Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Beijing, Fuzhou, Guangzhou, Zhengzhou, Nanjing, Tianjin, Hanzhou
2024-05-24
Recruiting
Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials
NCT06612632Cancer
DrugToripalimab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
100
Beijing
2024-05-24
Active, closed
Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
NCT06490107Biliary Tract Cancer
DrugsTegafur Gimeracil Oteracil·Durvalumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
40
Beijing
2024-05-24
Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ50% (MK-1084-004/KANDLELIT-004)
NCT06345729Non-small Cell Lung Cancer
DrugsCalderasib·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
600
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Jiamusi
2024-05-24
Recruiting
MRD Response-adapted Allo-HSCT for Adverse-risk AML
NCT06301425Acute Myeloid Leukemia
Peking University People's Hospital
Not applicable
178
Beijing
2024-05-24
Recruiting
A Study of GQ1010 in Subjects With Advanced Solid Tumors
NCT06464055Advanced Malignant Solid Tumors
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 1/2
260
Beijing, Harbin, Tianjin, Wuhan, Zhengzhou
2024-05-23
Recruiting
Spectral CT in Radiotherapy for Cervical Cancer
NCT06433817Cervical Cancer, Radiotherapy
Peking Union Medical College Hospital
Observational
150
Beijing
2024-05-22
Recruiting
Acupuncture of Different Treatment Frequency in Chronic Plantar Fasciitis
NCT06284993Plantar Fasciitis, Chronic
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
80
Beijing
2024-05-21
Recruiting
Using the Chinese Indigenization FS Scale in the Diagnosis of Fibromyalgia๏ผš Specificity and Sensitivity in Clinical Practice
NCT06533410Fibromyalgia
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Observational
59
Beijing
2024-05-21
Rows per page Showing 3401–3500 of 5484
Previous 33 34 35 36 37 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=35

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.